GPER1 and breast cancer: Although tamoxifen and fulvestrant are used therapeutically to inhibit the 17beta-estradiol signaling pathway in breast cancer, it has been shown in an immortalized human breast cancer cell line (MCF7) that these drugs lead to an agonistic activation of GPER that results in stimulated proliferation via EGFR transactivation [2].